차세대 시퀀싱(NGS) 인포매틱스 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the next-generation sequencing informatics market size is expected to grow from USD 2.64 billion in 2025 to USD 3.01 billion in 2026 and is forecast to reach USD 5.78 billion by 2031 at 13.95% CAGR over 2026-2031.

This report is Segmented by Offering (NGS Informatics Software, NGS Informatics Services, and NGS Informatics Platforms), Deployment Mode (Cloud-Based, and More), Application (Drug Discovery, and More), End User (Hospitals, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Next-Generation Sequencing Informatics Market Trends and Insights

Widening Clinical & Research Use-Cases of Genomics

Oncology programs now rely on comprehensive panels that match patients to targeted therapies, a shift that is propelling precision-medicine revenues at a 16.4% CAGR through 2030. In Frederick Health, embedding GenomOncology's platform inside Expanse Genomics triggered therapy adjustments for 96 patients and multiplied clinical-trial referrals by 28-fold within six months. Rare-disease diagnostics are benefiting from long-read sequencing, and Azenta's clinically validated test is uncovering structural variants most short-read workflows miss. Academic consortia are also scaling: the Alliance for Genomic Discovery has completed 250,000 whole genomes, enlarging training sets for drug-target identification. As these programs expand, hospitals and biopharma alike demand informatics platforms that translate complex datasets into bedside decisions, reinforcing recurrent-revenue models across the next-generation sequencing informatics market.

Sustained Decline in Sequencing Cost per Genome

Platforms from Ultima Genomics and Roche SBX are pushing per-sample costs toward USD 100 and raising throughput to seven 30X genomes per hour, respectively. Lower entry costs have unlocked population-scale projects, leading Singapore's national precision-medicine roadmap and India's GenomeIndia effort to commission tens of thousands of new genomes. Illumina MiSeq i100 systems, tailored for laboratories that lack cold-chain logistics, are widening uptake in emerging economies. As sequencing capital intensity wanes, data-analysis capacity rather than read generation is becoming the primary bottleneck, shifting budget allocations toward software subscriptions and managed services inside the next-generation sequencing informatics market.

Fragmented Global Data-Privacy & Sovereignty Regulations

The U.S. Department of Justice now restricts bulk genomic exports to designated "countries of concern," compelling enterprises to install technical safeguards and submit annual audits starting October 2025. Europe's GDPR already mandates explicit consent for secondary use, and several APAC nations have introduced data-localization clauses that complicate multi-center studies. Providers must therefore build region-segregated clouds or pursue federated-learning models, steps that inflate compliance overheads by double digits and may slow deployment cycles inside the next-generation sequencing informatics market.

Other drivers and restraints analyzed in the detailed report include:

1. Mainstream Adoption of Cloud & Hybrid Compute Architectures
2. Convergence of AI/ML with Genomic Data Pipelines
3. Shortage of Clinically-Trained Bioinformaticians & Validation Experts

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

NGS informatics software maintained 57.45% of next-generation sequencing informatics market share in 2025 and anchors most primary and tertiary workflows, with Illumina DRAGEN and Emedgene Explainable AI driving incremental accuracy gains. Custom plug-in ecosystems, semantic-search modules and AI-assisted curation engines transform static variant files into interactive clinical reports within minutes. Cloud-native platforms, though smaller today, are expanding at a 15.55% CAGR, bundling workflow management, compliance dashboards and pay-as-you-go compute into unified workspaces that appeal to laboratories with limited in-house bioinformatics staff.

Service providers-ranging from managed-analysis shops to bespoke pipeline developers-remain indispensable for organizations lacking internal specialists. The Clinical and Laboratory Standards Institute's structured worksheets now guide validation, yet many hospital labs still outsource tertiary-interpretation tasks. As platforms integrate drag-and-drop interfaces and container orchestration, they further erode traditional silos and enlarge the total addressable segment of the next-generation sequencing informatics market.

Cloud installations accounted for 63.40% of the next-generation sequencing informatics market in 2025, fueled by the need to spin up tens of thousands of CPU-hours without capital expenditure. Providers such as Google Cloud offer turnkey genomics workbenches with petabyte-scale object stores and integrated AI model hubs that reduce the mean time-to-answer for multi-omics queries.

On-premise clusters persist where data cannot leave firewalls, but steady equipment depreciation and rising energy costs are prompting a migration to hybrid set-ups. The hybrid model combines in-house secure storage for raw reads with cloud-based secondary analysis, allowing compliance with emerging sovereignty statutes while maintaining elasticity. These configurations are expected to post a 15.1% CAGR to 2031, expanding the footprint of the next-generation sequencing informatics market size for deployment solutions worldwide.

Complete Report Scope:

• By Offering
  • NGS Informatics Software
    • Primary Data Analysis Tools
    • Secondary Analysis (Alignment, Assembly, Variant Calling)
    • Tertiary Analysis & Interpretation
  • NGS Informatics Services
    • Managed & Hosted Services
    • Custom Bioinformatics & Pipeline Development
    • Training & Support Services
  • NGS Informatics Platforms
• By Deployment Mode
  • Cloud-based
  • On-premise
  • Hybrid
• By Application
  • Drug Discovery
  • Genetic Screening
  • Precision Medicine
  • Other Applications
• By End User
  • Hospitals and Clinics
  • Academics and Research Institutes
  • Pharmaceuticals Companies
  • Other End Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 41.70% of 2025 turnover, underpinned by deep research budgets, mature payer frameworks and an FDA stance that encourages adaptive AI in clinical genomics. Technology alliances are flourishing: NVIDIA, IQVIA and Mayo Clinic jointly train foundation models that crunch petabytes of multimodal patient data to accelerate trial matching. Tempus, meanwhile, became the first laboratory to feed structured somatic-variant results directly into Epic's Genomics module across more than 3,000 institutions, cementing clinical workflows that lean heavily on domestic analytics vendors.

Asia Pacific is projected to compound at 14.21% a year to 2031, propelled by Singapore's 10-year precision-medicine roadmap, Australia's PrOSPeCT cancer program and South Korea's K-MASTER initiative, each sequencing tens of thousands of genomes. India's contract-research sector, growing at 10.75%, complements device uptake; Illumina's MiSeq i100 aims squarely at labs lacking cold-chain shipping, enabling localized workflows in tier-2 cities. These moves collectively enlarge the region's slice of the next-generation sequencing informatics market size and lay a foundation for cloud-native collaborations that respect sovereign data laws.

Europe retains a solid foothold on the back of Horizon funding and a new European Commission regulation that obliges public-health labs to adopt whole-genome sequencing for pathogen surveillance starting 2025. Partnerships like Illumina-Sequentia Biotech showcase translational uptake in food safety. Middle East & Africa and South America remain nascent but promising; initiatives such as the Quad Cancer Moonshot inject genomic infrastructure and establish early footholds for vendors courting frontier-market growth across the next-generation sequencing informatics market.

1. Illumina
2. Thermo Fisher Scientific
3. QIAGEN
4. Roche
5. Agilent Technologies
6. DNAnexus Inc.
7. Fabric Genomics Inc.
8. Partek
9. PerkinElmer
10. Eagle Genomics Ltd.
11. DNASTAR
12. SoftGenetics LLC
13. Sapio Sciences LLC
14. PierianDx Inc.
15. BGI Shenzhen (MGI Tech)
16. Oxford Nanopore Technologies plc (Epi2Me)
17. Seven Bridges Genomics Inc.
18. Geneious Biologics (Biomatters Ltd.)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Widening Clinical & Research Use-Cases of Genomics
  • 4.2.2 Sustained Decline in Sequencing Cost per Genome
  • 4.2.3 Mainstream Adoption of Cloud & Hybrid Compute Architectures
  • 4.2.4 Convergence of AI/ML with Genomic Data Pipelines
  • 4.2.5 Regulatory Recognition of Genomic Software as Medical Device (SaMD)
  • 4.2.6 Integration of Genomic Insights into EHR & Precision-Medicine Workflows
• 4.3 Market Restraints
  • 4.3.1 Fragmented Global Data-Privacy & Sovereignty Regulations
  • 4.3.2 Shortage of Clinically-Trained Bioinformaticians & Validation Experts
  • 4.3.3 Escalating Long-Term Storage & Compute Costs for Genomic Datasets
  • 4.3.4 Lack of Interoperability Among Legacy LIMS/EHR & Modern Pipelines
• 4.4 Regulatory & Technological Outlook
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Offering
  • 5.1.1 NGS Informatics Software
    • 5.1.1.1 Primary Data Analysis Tools
    • 5.1.1.2 Secondary Analysis (Alignment, Assembly, Variant Calling)
    • 5.1.1.3 Tertiary Analysis & Interpretation
  • 5.1.2 NGS Informatics Services
    • 5.1.2.1 Managed & Hosted Services
    • 5.1.2.2 Custom Bioinformatics & Pipeline Development
    • 5.1.2.3 Training & Support Services
  • 5.1.3 NGS Informatics Platforms
• 5.2 By Deployment Mode
  • 5.2.1 Cloud-based
  • 5.2.2 On-premise
  • 5.2.3 Hybrid
• 5.3 By Application
  • 5.3.1 Drug Discovery
  • 5.3.2 Genetic Screening
  • 5.3.3 Precision Medicine
  • 5.3.4 Other Applications
• 5.4 By End User
  • 5.4.1 Hospitals and Clinics
  • 5.4.2 Academics and Research Institutes
  • 5.4.3 Pharmaceuticals Companies
  • 5.4.4 Other End Users
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
  • 6.3.1 Illumina Inc.
  • 6.3.2 Thermo Fisher Scientific Inc.
  • 6.3.3 QIAGEN N.V.
  • 6.3.4 F. Hoffmann-La Roche Ltd.
  • 6.3.5 Agilent Technologies Inc.
  • 6.3.6 DNAnexus Inc.
  • 6.3.7 Fabric Genomics Inc.
  • 6.3.8 Partek Incorporated
  • 6.3.9 PerkinElmer Inc.
  • 6.3.10 Eagle Genomics Ltd.
  • 6.3.11 DNASTAR Inc.
  • 6.3.12 SoftGenetics LLC
  • 6.3.13 Sapio Sciences LLC
  • 6.3.14 PierianDx Inc.
  • 6.3.15 BGI Shenzhen (MGI Tech)
  • 6.3.16 Oxford Nanopore Technologies plc (Epi2Me)
  • 6.3.17 Seven Bridges Genomics Inc.
  • 6.3.18 Geneious Biologics (Biomatters Ltd.)

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment